NCT00103376 2018-11-05
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
Medical University of South Carolina
Phase 2 Terminated
Clinical Trials
4 trialsNCT00183937 2018-05-14
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
University of Southern California
Phase 2 Completed
NCT00425503 2014-04-21
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
Baylor College of Medicine
Phase 2 Completed
NCT00193232 2010-07-28
Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer
SCRI Development Innovations, LLC
Phase 2 Completed